📊 Backtest📒 Journal Updated 29/09/2026
← ⚡ Catalyst
📐 Simulate Position
STALE?Report written 7 days ago · at $35.12entry levels may be stale — re-check before acting

AGIO

SpeculativeMID CAP
Agios Pharmaceuticals, Inc. · NASDAQ · Biotechnology / Rare Hematology
$35.12
▲ 2.09%
MCap $2.04B
52-week range $22.24-$46.00; up 2.09% over the last 24h into the PDUFA window
BusinessRare-disease biopharma — PYRUKYND/AQVESME (mitapivat) is the only approved pyruvate-kinase activator for hemolytic anemias, now filed for sickle cell disease
Thesis

The FDA has a Priority Review PDUFA decision due Nov 1, 2026 on mitapivat's supplemental NDA for sickle cell disease, backed by durable Phase 3 RISE UP data (lower transfusion needs, better PROs, clean safety). Agios has direct precedent: the same drug's thalassemia approval (Dec 2025) moved the stock +19.97% in a single session. Consensus target $42.33 (BofA $46, H.C. Wainwright $54, JPMorgan $31) implies +20.5% upside — the widened 20% gate is cleared, but with the thinnest margin of this batch given the target dispersion. Base case (+20%) sits near consensus and assumes approval on-label with no surprise; that's inside the lane's realized 14d P75 of +6.6% only if measured point-in-time — the written Base still assumes a multi-week re-rating horizon through the PDUFA date itself, not the fixed 14-day window.

📝 Primary Verdict · Core Holding
BUYSpeculative

Measured median at-catalyst return across the core lane is -6.9% (n=54) — buying at today's $35.12 is not the default entry; the $31-32 pre-PDUFA dip zone is preferred. Agios has direct precedent for this exact setup: the same drug's thalassemia approval moved the stock +19.97% in one session. Size modestly given the binary CRL risk and the widest analyst-target dispersion in this batch.

71
score / 100 ⓘ
⚡ Catalyst
💊 Mitapivat Sickle Cell Disease PDUFA Decision33 DAYS

FDA Priority Review decision on the sNDA for mitapivat in sickle cell disease, backed by Phase 3 RISE UP data showing durable hemoglobin gains and lower transfusion needs. Same drug already has a US approval precedent in thalassemia (Dec 2025).

Nov 1, 2026
🎯 Entry Point
Entry 1
$35.12
Current priceNow
Entry 2PREFERRED
$31–32
Pre-PDUFA dip zoneIf dips
Entry 3
$27.00
Deep dip / de-risked entry ahead of the decisionIf broader biotech sells off
✅ Take Profit
TP1
Base case — on-label approval, in line with consensus
$42.14
+20%
TP2
Bull case — approval + upgraded sickle cell peak-sales estimates
$47.41
+35%
TP3 🌙
Moon case — approval + BD/takeout interest · matches H.C. Wainwright's $54 target
$54.44
+55%
🔴 Stop Loss
Tight Stop
Wider than the core lane's overall medianMAE (-14%) to give room ahead of a binary regulatory event
$28.8
-18%
Hard Stop
Near the 52-week low — signals the market is pricing a CRL
$24.58
-30%
Risk / Reward
Tight stop vs TP2, off current price
1.9 : 1
⚠ Fair R/R — thinnest of this batch given target dispersion
📅 Estimate Date
Mitapivat SCD PDUFA Decision
Priority Review — FDA decision date
Nov 1, 2026
Q3 2026 Earnings
AQVESME thalassemia launch trajectory + SCD launch-readiness commentary
Nov 2026
📈 Stock Timeline
1 snapshot · Sep 29
First snapshot — check back next week
Score
66
Sep 29
TP2 Target
$47.41
Sep 29
Rank
#10
Sep 29
📈 Possible Up % — Scenario Spread
Bear
-35%
$22.83
Base
+20%
$42.14
Bull
+35%
$47.41
Moon
+55%
$54.44
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed hiked to 3.75-4.00% on Sep 16, 2026 (first hike since 2023); next FOMC is Oct 27-28, 2026 — just 4 days before the Nov 1 PDUFA, so a hawkish surprise there could compress risk appetite right into the binary event.
Inflation
The hike is inflation-driven, not growth-driven — biotech approval catalysts are historically idiosyncratic and less macro-beta than most of this batch, but a risk-off week would still amplify any negative PDUFA surprise.
Sector Impact
Biotech with commercial revenue (AGIO has a marketed thalassemia drug) is more insulated from rate moves than pre-revenue names, since the near-term cash flow story doesn't depend on fresh financing.
Summary
MEDIUM macro risk — Agios already has commercial revenue and doesn't need new financing to clear this catalyst, but the Oct 27-28 FOMC lands 4 days before the PDUFA and could add noise into the event.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

H.C. Wainwright
Buy$54+54%
BofA Securities
Buy$46+31%
JPMorgan
Neutral$31-12%
Consensus
Buy$42.33+21%
current price $35.12
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

AGIO✅ GoodDec 2025
+19.97%
in 1 day
AQVESME (mitapivat) FDA approval for thalassemia anemia — same drug, same company, direct precedent for the Nov 1 sickle cell PDUFA
The single best comparable available — identical mechanism, same sponsor, only the indication differs
MDGL✅ GoodMar 2024
+11%
in 1 day
Rezdiffra (resmetirom) approval — first-ever FDA-approved MASH therapy
Smaller move than typical because the approval was well-anticipated and already large-cap — illustrates the downside case where a clean approval is mostly priced in
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-18% / -25%) only when trading the earnings spot — not for the core holding (use the -18% / -30% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
+5% to +15%1-2 weeks before the PDUFA date

Priority-review PDUFA names typically see a modest drift into the decision date as positioning builds, though moves 40-200%+ in either direction are common on the day itself given how binary the outcome is

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +25%
range: +11% to +45%· Dec 2025
Agios's own precedent: AQVESME thalassemia approval (Dec 23, 2025) moved AGIO +19.97% same day (open $24.85, close $29.50). Sector context: small-cap priority-review approvals typically run +30-100%+, though a well-anticipated approval on an already-large-cap name can be muted — see Madrigal's +11% on the first-ever MASH approval (Mar 2024), where much of the move was pre-priced.
❌ Catalyst Missavg -25%
range: -15% to -50%· 2024-2025 priority-review cohort
Industry-wide priority-review CRL pattern: 'fixable' (CMC/procedural) CRLs average -15% to -35%; 'fatal' (efficacy/safety) CRLs average -40% to -80%. No direct Agios CRL precedent exists for mitapivat — this is a category-level reference, not a company-specific case.
💼Spot Position Sizing
How the recommended % is derived
4%
of portfolio

Binary regulatory catalyst with real CRL tail risk despite Priority Review and positive Phase 3 data — size modestly even though Agios has commercial revenue to cushion a miss

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-18%($28.8)
Below this, the market is pre-pricing a negative outcome — reassess before the date
After Catalyst (Bad Result)-25%
On a CRL, exit on confirmation rather than waiting for the resubmission timeline
📎 Sources

Generated 2026-09-29 · Not financial advice